Neurocrine Biosciences, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $713.0M | $233.0M | $251.1M | $262.9M | $340.8M | $187.1M | $112.3M | $141.7M |
| Accounts Receivable | $686.8M | $479.1M | $439.3M | $350.0M | $185.5M | $157.1M | $126.6M | $57.4M |
| Inventory | $69.0M | $57.4M | $38.3M | $35.1M | $30.5M | $28.0M | $17.3M | $10.9M |
| Total Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $972.8M | $1.02B | $831.0M | $737.8M |
| Property, Plant & Equipment | $89.8M | $82.6M | $70.8M | $58.6M | $58.6M | $44.6M | $41.9M | $33.9M |
| Goodwill | — | $5.7M | $5.8M | $5.4M | $0 | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | $36.5M | $35.5M | $37.2M | $0 | — | — | — |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993.2M |
| Liabilities | ||||||||
| Accounts Payable | $674.3M | $461.6M | $448.8M | $347.6M | $225.8M | $168.7M | $141.3M | $13.8M |
| Total Current Liabilities | $743.4M | $507.7M | $654.8M | $537.7M | $245.8M | $186.5M | $565.3M | $88.2M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $660.9M | $698.5M | $608.5M | $669.1M | $512.4M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $447.7M | $29.2M | $-157.1M | $-406.8M | $-635.8M | $-725.4M | $-1.13B | $-1.18B |
| Total Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $636.9M | $480.8M |